CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Beleodaq for Peripheral T-Cell Lymphoma – Detail

Project Number PC0139-000
Brand Name Beleodaq
Generic Name Belinostat
Tumour Type Lymphoma
Indication Peripheral T-Cell Lymphoma (PTCL)
Funding Request For the treatment of patients with relapsed or refractory PTCL
Review Status Withdrawn
Clarification Servier Canada Inc. has notified pCODR that the Category 2 submission requirements for the pre NOC submission of Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (PTCL) cannot be met at this time. As per pCODR Procedures C3.1.6, the pCODR program has stopped the review.
Pre Noc Submission Yes
NOC Date
Manufacturer Servier Canada Inc.
Sponsor Servier Canada Inc.
Submission Date June 29, 2018
Submission Deemed Complete July 9, 2018
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ July 16, 2018
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.